INULA GROUP
Acquired by
ARDIAN
INULA GROUP acquired by ARDIAN
Target
INULA GROUP
Acquirer
ARDIAN
Context
Ardian acquired a majority stake in Inula from Vendis Capital and founder Dominique Baudoux. The founder and Vendis Capital retained reinvestment options, while the CEO and the management team reinvested significantly to increase their equity stake. The acquisition aimed to leverage Ardian's global footprint to accelerate Inula's expansion in the US, Italy, and Germany, and to pursue buy-and-build opportunities in the fragmented aromatherapy market.
INULA GROUP, which reported an EBITDA margin of LOGIN in 2017, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 12.8x average currently observed in the Healthcare & Pharma sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Inula is a leading Belgian group specializing in natural therapies and phytotherapy. It operates through three flagship brands: Pranarom (scientific aromatherapy/essential oils), HerbalGem (concentrated gemmotherapy), and Biofloral (Bach flowers and floral extracts). The group is distinguished by its medical and scientific approach to natural products, sold primarily through pharmacies and organic specialty stores.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with INULA GROUP
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.